New Chronic Hepatitis B Virus Findings from Ningbo Yinzhou No. 2 Hospital Described [The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis]

摘要

2021 SEP 29 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - New research on chronic hepatitis B virus is the subject of a new report. According to news reporting out of Ningbo, People's Republic of China, by NewsRx editors, research stated, "Although most chronic hepatitis B (CHB) patients achieve effective virological suppression after receiving long-term nucleos(t)ide analogs (Nucs) therapy, the safety of off-therapy is controversial under the monitor. We identified studies through searching PubMed, Embase, Cochrane Library, and Web of Science from January 1990 to February 2021." The news editors obtained a quote from the research from Ningbo Yinzhou No. 2 Hospital: "The eligible studies compare the long outcomes between discontinued and continued Nucs treatments groups among CHB patients. This study was conducted to investigate long-term outcomes, including biochemical, serological, and virological outcomes, as well as hepatocellular carcinoma (HCC) development rate between discontinued and maintained Nucs therapy groups among CHB patients. Five eligible studies covering 1,425 patients were selected for meta-analysis.